The New Gold Standard

Impact analytics are raising the bar in value-based contracting (VBC) and outcomes-based compensation (OBC).

With guidance from business coalitions on health, human capital consulting firms, and data science organizations; pioneering employers and other healthcare purchasers are sharing a broad range of pharmacy benefit and medical insurance claims data.

They’re studying correlated and causal relationships among payers, providers, and products and desired business endpoints. 

For example, with dynamic dashboards and scorecards powered by Alteryx, Tableau, and related solutions, these healthcare purchasers can get real-time or near real-time reporting on…

  1. economic, clinical, and humanistic outcomes (ECHOs);
  2. per capita costs, population health, and patients/practitioner experiences (i.e., the Triple/Quadruple/Quintuple Aim);
  3. the incidence, prevalence, and cost of diseases and other adverse conditions;
  4. the well-being, productive capacity, and socioeconomic status of individuals, organizations, and communities; and
  5. the speed of progress toward better-aligned stakeholders, a better functioning society, and improved human flourishing.

Data sharing and data science create unprecedented transparency around clinical practice patterns and their effects—so much so that real-world data (RWD) collaborations are proliferating and real-world evidence (RWE) of safety, efficacy, and cost-effectiveness is emerging as the new gold standard in value-based contracting (VBC) and outcomes-based compensation (OBC).

Those carrying the burden of healthcare cost escalation are comfortable giving healthcare’s superstars—the health industry’s good actors—the rewards they deserve. 

At the same time, healthcare’s purchasers want to give mercenary bad actors “no place to hide.”

Interested in learning more?

Reimbursement IQ—and our longstanding strategic partners at Central IQ—offer executive briefings essential to success in an era of 360-degree performance, outcomes, and impact accountability.

Contact us for more information on how to get your leadership and work teams more in the know. Call us today at +1 949-336-1691 or schedule a Zoom at https://bit.ly/3MQ2MoG.

Similar Posts

  • A Payment Manifesto

    Reimbursement IQ team members—and our longstanding partners at Central IQ—deliver source-of-payment strategies and support services that reduce the incidence, prevalence, and cost of diseases and other health challenges. We facilitate patient access to the industry’s most safe, effective, and cost-saving healthcare products and services in direct-to-consumer (DTC) and managed markets (the latter subject to third-party…

  • Healthcare's Transformation

    Founded in 1988, Reimbursement IQ provides analytical, strategic, and hands-on support services to forward-thinking innovators, entrepreneurs, and executives. With support from our longstanding strategic partners at Central IQ, we ensure client’s category-creating products, services, and solutions generate unparalleled returns on investment (ROIs) and have the best performance, outcomes, and impacts possible. Our expert team works…

  • Performance, Outcomes, and Impact Analytics

    The Reimbursement IQ subject matter experts—in collaboration with our longstanding strategic partners at Central IQ—are offering briefings on “Performance, Outcomes, and Impact Analytics” to innovators, entrepreneurs, and executives within Life Science companies. These Zoom-based or remote briefings can help transform Medical Affairs, HEOR/Value, Market Access, and Commercialization (Marketing and Sales) functions by revealing the extreme…

  • Market Access

    In the U.S. healthcare market, market access refers to the degree to which health-related products, services, and solutions can be identified, researched, purchased, used, and evaluated by individuals, organizations, and communities.  Complete market access is evidenced by the unrestricted flow of information, money, manpower (e.g., clinicians), materials (e.g., products), and methods (e.g., services) under “free market” conditions…